CytRx completes patient enrollment in tamibarotene Phase 2b study
Oral retinoid compound tamibarotene, which was designed to be superior to all trans-retinoic acid (ATRA) by binding to the molecular target more selectively, proved to be 10 times
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.